Premium
Tenofovir: Quo Vadis Anno 2012 (Where Is It Going in the Year 2012) ?
Author(s) -
De Clercq Erik
Publication year - 2012
Publication title -
medicinal research reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.868
H-Index - 130
eISSN - 1098-1128
pISSN - 0198-6325
DOI - 10.1002/med.21267
Subject(s) - emtricitabine , efavirenz , sexual transmission , darunavir , medicine , virology , rilpivirine , human immunodeficiency virus (hiv) , tenofovir , elvitegravir , pharmacology , microbicide , antiretroviral therapy , viral load
Twenty years after its original discovery, tenofovir has acquired a crucial position in the fight against human immunodeficiency virus ( HIV ). First, tenofovir disoproxil fumarate ( TDF ) is not only efficacious against, and has been licensed for the treatment of HIV ( AIDS ), but also HBV (hepatitis B ). Second, for the treatment of HIV infections, TDF can be used in combination with other anti‐ HIV drugs, such as emtricitabine (combination termed T ruvada®) and T ruvada can be further combined with efavirenz, rilpivirine, elvitegravir, atazanavir, or darunavir, as a single once‐daily oral pill. Third, T ruvada can be used prophylactically to prevent transmission of HIV infection. And fourth, to prevent sexual HIV transmission, tenofovir could also be used topically (i.e., as a vaginal gel). © 2012 Wiley Periodicals, Inc. Med Res Rev., 32, No. 4, 765‐785, 2012